Skip to content
Home
Visit our other Journals
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Visit
Diseases
Alzheimer's Disease
Dementia
Dementia with Lewy Bodies
Frontotemporal Dementia
Vascular Dementia
Mild Cognitive Impairment
View all Diseases
Topics
Diagnostics
Biology
Biomarkers
Treatment
Clinical Care
Prevention
View all Topics
Conferences
AAIC 2023
BNA 2023
AD/PD 2023
ARUK 2023
CTAD 2022
AAIC 2022
View all Conferences
Features
Podcasts
About
Supporter
Expert Index
Editorial Board
Editorial Team
Editorial Policy
Contact
Sign up
Trial Updates
1:56
HERITAGE: the effect of lifestyle interventions in at-risk elderly communities in China
Xin Xu
• 19 Jul 2023
3:04
Racial and ethnic minorities more likely to be excluded from trials based on biomarker prescreening
Doris Molina-Henry
• 18 Jul 2023
2:40
Phase I trial of NK cell therapy in advanced Alzheimer’s disease
Paul Y Song
• 18 Jul 2023
3:28
How do genetic scores impact the value of lifestyle interventions?
Alina Solomon
• 18 Jul 2023
3:06
A review of current clinical trials in dementia with Lewy bodies
Carla Abdelnour
• 17 Jul 2023
2:28
Ongoing concerns regarding lecanemab: efficacy & adverse events
Philip Tipton
• 27 Apr 2023
4:07
Phase II study of NE3107 in degenerative dementias
Joseph Michael Palumbo
• 26 Apr 2023
18:48
Boosting neurogenesis with NA-831: Phase III trial update
Lloyd Tran
• 24 Mar 2023
1:11
Potential clinical meaningfulness of donanemab data
Rebecca Edelmayer
• 18 May 2023
1:26
Topline donanemab results: most positive Phase III data to date
Rebecca Edelmayer
• 18 May 2023
3:49
Updates on anti-amyloid monoclonal antibodies for AD in Phase III trials
Philip Tipton
• 27 Apr 2023
4:01
Use of AD blood-based biomarkers for trial enrolment
Philip Tipton
• 27 Apr 2023
2:26
Why have anti-amyloid monoclonal antibodies performed differently in Phase III trials
Stephen Salloway
• 19 Apr 2023
2:48
TRAILBLAZER-ALZ 4: direct comparison of donanemab and aducanumab
Stephen Salloway
• 19 Apr 2023
1:50
Safety results of the Phase III gantenerumab GRADUATE I and II studies
Stephen Salloway
• 19 Apr 2023
4:23
Phase II trial of AR1001 as a potential treatment for Alzheimer’s disease
David Greeley
• 28 Mar 2023
1
2
3
4
5
Next